Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Nicotine is consistently described as one of the most addictive drugs in existence. It activates the mesolimbic reward pathway and induces long-term ΔFosB expression in the nucleus accumbens, resulting in strong psychological dependence. Discontinuation produces affective withdrawal symptoms including anxiety, irritability, intense craving, and anhedonia.
Nicotine produces significant physical dependence with chronic use. Withdrawal symptoms include somatic effects such as mild motor dysfunction and tremor, alongside depression, restlessness, insomnia, and in the long-term with abstinence, weight gain. Withdrawal symptoms peak within one to three days and can persist for several weeks, though withdrawal is not life-threatening.
The median lethal dose in humans is unknown. Earlier estimates suggested approximately 60 mg for adults, though more recent analysis indicates the lower limit for fatal outcomes is likely 500-1000 mg of ingested nicotine (6.5-13 mg/kg) for adults. Lethal doses occur at significantly lower amounts in children. Nicotine has relatively high toxicity compared to many other alkaloids. Poisoning rarely results in significant morbidity or death except in children, where poisonous and lethal levels occur at lower doses per kilogram of body weight.
| Species | Route | Value |
|---|---|---|
| mouse | oral | 24 mg/kg |
Acute use causes transient increases in heart rate, blood pressure, and systemic vasoconstriction including coronary arteries; long-term exposure may impair endothelial function and potentially contribute to atherosclerosis, with cardiac arrhythmias primarily a concern in individuals with underlying heart disease. Short-term nicotine use in healthy individuals poses little cardiovascular risk.
Heavy chronic use is associated with less efficient brain network architecture and disruptions in topological organization of brain networks; adolescent exposure may impair neurodevelopment up to age twenty-five, and some research suggests potential damage to medial habenula neurons regulating nicotine avoidance behaviors in chronic users.
Nicotine is considered a possible teratogen in humans; it crosses the placenta and negatively affects fetal brain development, with prenatal exposure associated with lower birth weight, increased risk of miscarriage and stillbirth, and potential long-term metabolic and neurobehavioral consequences in offspring.
Chronic exposure suppresses both innate and adaptive immune responses, downregulating cell-mediated immunity against infections and potentially reducing immune surveillance against neoplastic diseases.
May promote and aggravate periodontal diseases including periodontitis and gingivitis, particularly in the presence of harmful oral microorganisms.
Seizures are documented only at toxic or overdose-level doses and do not occur at typical recreational or therapeutic doses. Lethal nicotine poisoning rapidly produces seizures, and death from respiratory paralysis may occur within minutes of a severe overdose.
Tobacco first arrived in Europe during the early 1530s, brought back by Spanish explorers from the Americas. The plant quickly gained a reputation as a medicinal wonder, with smoking believed to offer protection against various illnesses, including the plague. This perception of tobacco as a "holy…
Approved pharmaceutical product available through regulated channels. Nicotine replacement therapy products such as transdermal patches (e.g., Nicorette Invisipatch) are marketed for smoking cessation. Not classified as a controlled substance.
Nicotine is classified as an approved pharmaceutical substance with ongoing investigational applications. Available in both prescription and over-the-counter formulations including transdermal patches, polacrilex lozenges, and gums marketed for smoking cessation therapy. Not scheduled as a controlled substance.
7 sources cited
